Selecta/Sobi Gout Drug Numerically, Not Significantly, Beat Krystexxa

SEL-212 Bested Horizon’s Drug But A New Standard Is Emerging

 
• By Mandy Jackson

Analysts have mixed opinions about whether a Phase IIb study of SEL-212, which Selecta recently licensed to Sobi, helps the drug’s commercial potential versus Horizon’s Krystexxa.

On a purple background a stethoscope with yellow list with text GOUT
Selecta and Sobi already have started Phase III trials for SEL-212 • Source: Shutterstock

More from Clinical Trials

More from R&D